Freeman Robert Thomas

Freeman Robert Thomas, then-CFO, sold 250,000 shares of ALHC at $15.58 per share for $3,895,775 on 2025-03-04 via 10b5-1 plan

Freeman Robert Thomas, who was CFO at the time, executed a scheduled sale of 250,000 shares at $15.58 on 2025-03-04 under a pre-arranged 10b5-1 trading plan, reducing his holdings from 1,885,849 shares to 1,635,849 shares. The sale represented a -13.3% reduction in his prior holdings. As a 10b5-1 transaction, this trade was scheduled in advance rather than discretionary, which constrains interpretation to the mechanical fact of the disposition without regard to market timing. The former CFO retains 1.64M shares post-transaction, maintaining a substantial ongoing position in Alignment Healthcare.

Freeman Robert Thomas, then-CFO, executed 3 scheduled sales totaling 143,561 shares for $1,585,755.26 under 10b5-1 plan

Freeman Robert Thomas, who was CFO at the time, conducted 3 separate sales totaling 143,561 shares for $1,585,755.26 at an average price of $11.05 per share, executed across three consecutive trading days (September 11-13, 2024). This transaction is part of a pre-arranged 10b5-1 trading plan, meaning the sales were scheduled in advance rather than discretionary. Post-transaction, Freeman held 264,429 shares, representing a reduction of 143,561 shares (-35.2% vs pre-transaction holdings of 407,990 shares). As a scheduled plan transaction, this sale reflects a predetermined trading program and does not indicate discretionary market timing or conviction-based positioning.

CFO Freeman Robert Thomas sold 105,000 shares at ~$10.00 in 3 transactions, reducing holdings 20.2% from 519,429 to 414,429 shares

Freeman Robert Thomas, Chief Financial Officer of Alignment Healthcare, executed 3 separate sales totaling 105,000 shares for $1,050,236.30 over a 3-day period (July 17-19, 2024) at a blended average price of $10.00. The current stock price stands at $10.07, near its 52-week high of $10.07, following a 33.4% gain over 30 days and 93.6% over 90 days. The company is generating meaningful revenue ($628.6M in the latest quarter) with strong annual revenue growth of 27.2%, but remains unprofitable with a net loss of $46.5M over its most recent full fiscal year. The sale reduced the CFO's post-transaction holdings to 414,429 shares, representing a 20.2% reduction in his stake.